Skip to main content
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. — Investor Relations & Filings

Ticker · KROS ISIN · US4923271013 US Professional, scientific and technical activities
Open in API
Filings indexed 477 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US KROS

About Keros Therapeutics, Inc.

https://www.kerostx.com/

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics. The company develops engineered protein therapeutics designed to address a wide range of disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) superfamily of proteins. Its approach aims to selectively and potently modulate these signaling pathways to treat the underlying causes of various hematological and musculoskeletal diseases.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K current report filed under the Securities Exchange Act of 1934. It furnishes a press release under Item 7.01 (Regulation FD Disclosure) and includes no substantive financial statements or financial results. This type of SEC Form 8-K is a general regulatory announcement and does not fall under any specific categories like earnings release, board management change, or financial report. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-06-01 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-14 English
8-K
Regulatory Filings
2026-05-14 English
ARS - Keros Therapeutics, Inc. (0001664710) (Filer)
Annual Report
2026-04-22 English
DEF 14A - Keros Therapeutics, Inc. (0001664710) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English
8-K - KEROS THERAPEUTICS, INC. (0001664710) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Keros Therapeutics, Inc. It specifically states in Item 7.01 that the company updated its corporate presentation for use in meetings with investors and analysts, and that the presentation is attached as Exhibit 99.1. The document is short (3885 characters) and primarily serves to announce the update and availability of the investor presentation rather than containing detailed financial data or analysis itself. According to the 'Menu vs Meal' rule, such a document is an announcement of a report (the presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2026-03-04 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.